Arvinas to Join Upcoming Investor Conferences

Arvinas, Inc., a clinical-stage biotechnology company listed on Nasdaq under the ticker ARVN, has announced its participation in two significant investor conferences. The company, based in New Haven, Connecticut, focuses on developing a new class of drugs that utilize targeted protein degradation to treat various diseases.

The first event will be the Jefferies Global Healthcare Conference, scheduled for June 6 in New York City. Representing Arvinas will be John Houston, Ph.D., who serves as the Chairperson, Chief Executive Officer, and President, along with Noah Berkowitz, M.D., Ph.D., the Chief Medical Officer. Both will engage in a fireside chat to discuss the company’s progress and future plans. Interested parties can access a live audio webcast of this presentation on the Events + Presentations section of the company's website.

The second event is the Goldman Sachs 45th Annual Global Healthcare Conference, which will take place on June 10 in Miami. John Houston and Noah Berkowitz will again participate in a fireside chat. As with the Jefferies conference, a live audio webcast will be available on the company’s website for those who wish to listen in.

Arvinas is dedicated to enhancing the lives of patients afflicted with severe and potentially fatal diseases by creating therapies that degrade harmful proteins. The company leverages its proprietary PROTAC® Discovery Engine to develop proteolysis targeting chimeras, known as PROTACs. These targeted protein degraders are designed to harness the body's natural protein disposal mechanisms to selectively eliminate disease-causing proteins.

Arvinas has a robust pipeline that includes both preclinical and clinical-stage programs. Of particular note are three clinical-stage investigational programs: vepdegestrant for locally advanced or metastatic ER+/HER2- breast cancer, ARV-102 for neurodegenerative disorders, and ARV-393 for relapsed/refractory non-Hodgkin Lymphoma as well as other potential lymphomas.

In April 2024, Arvinas entered into a significant transaction with Novartis, which included a global license agreement for the development and commercialization of ARV-766, a clinical-stage PROTAC® androgen receptor protein degrader aimed at treating prostate cancer. This transaction was finalized in May 2024.

Arvinas continues to focus on its mission to develop innovative therapies that can make a substantial impact on patients' lives by targeting and degrading disease-causing proteins. The company’s leadership team’s participation in these high-profile investor conferences underscores its commitment to advancing its pipeline and engaging with the investor community.